Disc Medicine Completes Enrollment in Phase 3 APOLLO Trial for EPP Treatment

Event summary

  • Disc Medicine completed enrollment in the Phase 3 APOLLO trial for bitopertin in erythropoietic protoporphyria (EPP), expanding the study size to 183 participants due to high demand.
  • The trial is a double-blind, placebo-controlled study with co-primary endpoints focused on sunlight exposure and biochemical markers.
  • Results from the APOLLO study are expected in Q4 2026, with an FDA decision anticipated by mid-2027.

The big picture

Disc Medicine's rapid enrollment in the APOLLO trial highlights the critical need for effective treatments in the rare disease space. The company's focus on hematologic diseases positions it within a growing sector of precision medicine, where targeted therapies are increasingly gaining regulatory and commercial traction. The strategic acquisition of bitopertin from Roche in 2021 underscores Disc's commitment to developing first-in-class treatments for underserved patient populations.

What we're watching

Regulatory Pathway
Whether the APOLLO trial results will support a successful FDA submission and approval for bitopertin.
Market Demand
The pace at which Disc Medicine can capitalize on the unmet need for EPP treatments if bitopertin gains approval.
Execution Risk
How Disc Medicine manages the transition from clinical trials to potential commercialization, including manufacturing and distribution.

Related topics

Biotechnology